Compare Match Group Inc (MTCH) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Recursion Pharmaceuticals Inc — how do they compare? Match Group Inc trades at $41.46 (market cap $9.45B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B). The key difference: Match Group Inc is far larger — about 5.1× Recursion Pharmaceuticals Inc's market cap, and Match Group Inc pays a 1.94% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MTCH | RXRX | |
|---|---|---|
Market Cap | $9.45B | $1.86B |
Sector | Media | Health |
52-Week High | $42.44 | $6.79 |
52-Week Low | $28.90 | $2.84 |
Enterprise Value | $12.41B | $1.38B |
Dividend Yield | 1.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $41.15, down 1.7% today, near its consensus price target of $42.50. The stock shows a bullish technical signal with support at $41 and resistance at $42. Recent earnings beat expectations in Q2 2026, with Q3 2026 results pending. Revenue stability around $3.5B and a net income margin of 20.17% reflect solid profitability, though high debt levels pose a risk. Analysts are overwhelmingly positive with 53% buy ratings and no sell recommendations.
The outlook for MTCH is cautiously optimistic, driven by product innovation at Tinder and strong cash flow growth. Investment opportunities include potential upside to the $45 high price target and dividend payments. Risks include elevated long-term debt of $3.85B and competitive pressures in the dating app market. Investors should monitor Q3 2026 earnings for confirmation of growth trends.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
